These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17492598)

  • 1. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
    Tam VH; Louie A; Fritsche TR; Deziel M; Liu W; Brown DL; Deshpande L; Leary R; Jones RN; Drusano GL
    J Infect Dis; 2007 Jun; 195(12):1818-27. PubMed ID: 17492598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.
    Drusano GL; Liu W; Brown DL; Rice LB; Louie A
    J Infect Dis; 2009 Jan; 199(2):219-26. PubMed ID: 19049435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies.
    Vickers AA; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2007 Aug; 60(2):269-73. PubMed ID: 17556355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models.
    Smirnova MV; Vostrov SN; Strukova EV; Dovzhenko SA; Kobrin MB; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2009 Oct; 64(4):815-20. PubMed ID: 19671586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.
    Tam VH; Louie A; Deziel MR; Liu W; Drusano GL
    Antimicrob Agents Chemother; 2007 Feb; 51(2):744-7. PubMed ID: 17116679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mutant selection window in rabbits infected with Staphylococcus aureus.
    Cui J; Liu Y; Wang R; Tong W; Drlica K; Zhao X
    J Infect Dis; 2006 Dec; 194(11):1601-8. PubMed ID: 17083047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi.
    Intorre L; Vanni M; Di Bello D; Pretti C; Meucci V; Tognetti R; Soldani G; Cardini G; Jousson O
    J Vet Pharmacol Ther; 2007 Oct; 30(5):464-9. PubMed ID: 17803740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.
    Tam VH; Louie A; Deziel MR; Liu W; Leary R; Drusano GL
    J Infect Dis; 2005 Aug; 192(3):420-8. PubMed ID: 15995955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
    Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
    J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model.
    Oonishi Y; Mitsuyama J; Yamaguchi K
    J Antimicrob Chemother; 2007 Nov; 60(5):1030-7. PubMed ID: 17827137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.
    Leonard SN; Kaatz GW; Rucker LR; Rybak MJ
    J Antimicrob Chemother; 2008 Dec; 62(6):1305-10. PubMed ID: 18801920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing use of quinolones in the critically ill.
    Yang JC; Tsuji BT; Forrest A
    Semin Respir Crit Care Med; 2007 Dec; 28(6):586-95. PubMed ID: 18095222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM).
    Schafer JA; Hovde LB; Rotschafer JC
    J Antimicrob Chemother; 2006 Jul; 58(1):108-11. PubMed ID: 16735429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.